MissionIR Articles
-
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced DehydraTECH Delivers More CBD into the Body
The new version of the DehydraTECH delivery platform is suitable for use in pills, capsules and tablets for the pharmaceutical, medical and supplement markets DehydraTECH has demonstrated that it can deliver eight times more CBD…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Releases 2019 Annual and Special Meeting Results
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) on Friday announced the results of its 2019 annual and special meeting. Held on June 20, 2019, there were 43,217,711 company…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Continues to Demonstrate Effectiveness in Lab Testing
Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) patented drug-delivery platform, DehydraTECH, has exhibited continued success in recent animal lab tests by delivering cannabinoids to the bloodstream faster than conventional cannabinoid formulations (http://ibn.fm/pYSzq). A recent article discussing…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Technology Credited as Major Factor in 1906 Edibles Appeal
Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM) is credited as part of the major appeal of Nuka Enterprises LLC’s 1906 cannabis edibles. A recent article quotes Nuka CEO…
-
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers 475% More CBD to the Bloodstream
LXRP’s DehydraTECH has been shown to outperform conventional cannabis formulations and deliver 475 percent more CBD to the bloodstream in the first 15 minutes Compared to other industry formulations, DehydraTECH delivered cannabinoids quicker at industry-leading…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Opportunities for 1906 Edibles
LXRP has expanded its cannabis product relationship with Nuka Enterprises’ 1906 brand DehydraTECH enables 1906 chocolates to deliver on both function and flavor The company is expecting a tenfold increase in sales with expansion to…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files Patents for New DehydraTECH Innovation
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that it has identified improved performance features of a new version of the DehydraTECH(TM) delivery platform primarily suitable for…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM) Combined with Nanotech Delivers 1,137 Percent More CBD into Animal Brain Tissue
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that combining Lexaria’s DehydraTECH(TM) delivery technology with generic nanotech techniques has been proven to deliver 1,137% more cannabidiol (“CBD”)…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Nuka to Expand Cannabis Product Operations for DehydraTECH Powered Edibles
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that, through a major expansion in operations by Nuka Enterprises LLC, maker of 1906 cannabis edibles for high functioning…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Responds to High Demand for Cannabis-Infused Beverages
The company aims to promote healthier administration methods, eliminating the need for sweeteners to mask taste Lexaria’s mission is to save lives with its technology, which allows for delivery of drug molecules through ingestible means…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Outperforms Conventional Industry Formulations in Animal Testing
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing has proven that its DehydraTECH(TM) technology delivers cannabinoids to the bloodstream much more quickly and effectively…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Adds Four Members to Advisory Board, Renews Executive Contracts
LXRP recently added multiple highly respected experts to its scientific advisory board The company is readying for growth by ensuring executive continuity LXRP continues to conduct research regarding oral nicotine Lexaria Bioscience Corp. (CSE: LXX)…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters CBD-Beverage Formulation License Agreement via Subsidiary
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its entry into a definitive 5-year agreement, via its subsidiary Lexaria Hemp Corp. Under the agreement, Lexaria will provide…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters New Licensing Agreement, Strengthens Business Model
Lexaria continues to create a strong, revenue-generating business model to support its growing patent portfolio The company out-licenses disruptive delivery technology, giving licensees access to existing patents Lexaria entered into a new beverage license agreement…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Execs Sign Three-Year Contract Extensions, Ensuring Management Continuity
LXRP CEO Chris Bunka and President John Docherty have agreed to new, three-year contracts The new contract agreements are designed to provide management security with continuity of key officers The company recently canceled 1,140,000 stock…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology Improves Delivery of Nicotine, Cannabinoids
Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expands Advisory Board; Subsidiary Enters Beverage License Agreement
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) on Wednesday announced that, through its subsidiary Lexaria CanPharm ULC, it has entered a definitive 5-year agreement to provide Lexaria’s patented DehydraTECH(TM)…
-
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advancing DehydraTECH Drug Delivery Platform, Innovative Products
Lexaria Bioscience is focusing on its pioneering DehydraTECH drug delivery technology The company boasts a portfolio of unique products Lexaria continues to conduct research regarding DehydraTECH technology for oral nicotine Based in Kelowna, British Columbia,…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Retains Oak Hill Financial Inc. for IR Services
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) this morning announced that it has retained Oak Hill Financial Inc. to provide investor relations services to the company in compliance…
-
MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Renews Senior Management Contracts, Cancels Options
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced its successful negotiation of renewal management contracts with chief executive officer Chris Bunka and president John Docherty. According to…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial